Characterization of Antibody-Drug Conjugate Critical Quality Attributes Using the Agilent Cary 3500 UV-Vis Multizone Temperature Capability

Importance of the topic

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, creating a rapidly expanding class of targeted biotherapeutics. Monitoring critical quality attributes (CQAs) such as drug-to-antibody ratio (DAR) and aggregation is essential because these parameters directly influence safety, efficacy and immunogenicity in development and manufacturing of ADCs.

Goals and overview

This application note demonstrates how the Agilent Cary 3500 UV-Vis Multicell spectrophotometer with multizone temperature control can be used to determine DAR and aggregation index of ADCs. The study assesses accuracy, throughput and ease of use by mixing ADC and unconjugated antibody at defined ratios and monitoring temperature-dependent changes in conjugation and aggregation.

Methods and instrument

The ADC analog of trastuzumab (Herceptin) conjugated to DM1 was diluted and mixed at various proportions to produce DAR values from 0 to 3.5. Two key calculations were applied:

• Average DAR from absorbance ratio at 252 nm and 280 nm using known extinction coefficients.
• Aggregation index from absorbance at 350 nm relative to 280 nm.

Instrument setup:

• Agilent Cary 3500 UV-Vis Multicell spectrophotometer with eight-position multicell Peltier detector module
• Multizone temperature control across four cuvette pairs (60–90 °C)
• Cary UV Workstation software with multizone add-on and custom equation capabilities
• Vivaspin centrifugal concentrators, Agilent rectangular 10 mm cuvettes, Milli-Q water

Main results and discussion

Measurement of ADC/antibody mixtures yielded UV-Vis spectra with distinct peaks at 252 nm (DM1) and 280 nm (antibody). Calculated DAR values scaled linearly with the percentage of conjugated ADC. Increasing temperature from 60 °C to 90 °C led to a slight decrease in DAR, attributable to thermally induced aggregation. Time-course studies at 90 °C showed a progressive rise in aggregation index over 120 minutes, confirming the method’s ability to monitor stability under stress.

Benefits and practical applications

This approach offers:

• Simultaneous analysis of up to four samples at different temperatures for rapid comparative studies
• High throughput and precise thermal control to assess stability and conjugation efficiency
• Custom equation functionality for automated DAR and aggregation calculations
• Compatibility with 21 CFR Part 11 via Agilent OpenLab integration for regulated environments

Future trends and applications

Advancements may include integration of real-time kinetic measurements, expanded spectral deconvolution for multi-drug conjugates, and coupling with automated sample handling. Such developments could streamline ADC development pipelines and support broader quality control in biopharmaceutical manufacturing.

Conclusion

The Agilent Cary 3500 UV-Vis Multicell spectrophotometer with multizone temperature control delivers a robust, user-friendly platform for rapid determination of DAR and aggregation index in ADCs, facilitating reliable CQA assessment during development and production.

Reference

1. Wag A. et al. Challenges and New Frontiers in Analytical Characterization of Antibody-Drug Conjugates. MAbs. 2018;10(2):222–243.
2. Li W. et al. Antibody Aggregation: Insights from Sequence and Structure. Antibodies (Basel). 2016;5(3):19.
3. Chen Y. Drug-to-Antibody Ratio (DAR) by UV/Vis spectroscopy. Methods Mol. Biol. 2013;1045:267–273.
4. Abedi M. et al. Novel Trastuzumab-DM1 Conjugate: Synthesis and Bio-Evaluation. J Cell Physiol. 2019;234(10):18206–18213.
5. Padmanaban A., Menon S. Characterization of mAb Aggregation. Agilent application note. 2020.